Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$462.88 USD
-0.27 (-0.06%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $462.85 -0.03 (-0.01%) 5:20 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$462.88 USD
-0.27 (-0.06%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $462.85 -0.03 (-0.01%) 5:20 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Zacks News
Travere (TVTX) Announces Data on Rare Kidney Disease Drug
by Zacks Equity Research
Travere (TVTX) announces positive interim data from the ongoing study of its investigational candidate, sparsentan, for the treatment of IgAN, a rare kidney disorder. Resultantly, the stock rises
Moderna (MRNA) Begins Rare Disease Study, Inks Supply Agreement
by Zacks Equity Research
Moderna (MRNA) doses first patient in phase I/II study with mRNA-3705 for the treatment of a rare multi-organ disorder. The company also revises the supply agreement with the Canadian Government for its COVID vaccine.
Sesen's (SESN) Bladder Cancer Drug Vicineum Gets CRL From FDA
by Zacks Equity Research
Sesen's (SESN) biologics license application filed for Vicineum to treat BCG-unresponsive non-muscle invasive bladder cancer fails to secure approval. The stock declines resultantly.
Pfizer (PFE) Gets Fast Track Tag for Wilson Disease Candidate
by Zacks Equity Research
The FDA bestows a Fast Track designation to Pfizer (PFE) and partner Vivet Therapeutics' clinical-stage gene therapy, VTX-801, for the treatment of Wilson disease.
Organon's (OGN) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Organon's (OGN) earnings and revenues beat estimates in the second quarter of 2021. Stock up in pre-market trading.
Perrigo (PRGO) Q2 Earnings Lag, Sales Hurt by Weak Cold Season
by Zacks Equity Research
Perrigo (PRGO) reports dismal second-quarter 2021 results. Stock down.
ChemoCentryx (CCXI) Q2 Loss Wider Than Expected, Sales Down
by Zacks Equity Research
ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the second quarter and misses on sales.
Axsome (AXSM) Q2 Earnings Top, AXS-05 Approval Likely Delayed
by Zacks Equity Research
Axsome Therapeutics (AXSM) reports narrower-than-expected Q2 loss. Yet, share price falls steeply after it notified of a potential delay in the approval of AXS-05 for major depressive disorder
QIAGEN (QGEN) Gains FDA's EUA for SARS CoV-2 Antigen Test
by Zacks Equity Research
QIAGEN's (QGEN) QIAreach SARS CoV-2 Antigen Test can detect SARS CoV-2 antigens in 2-15 minutes and can process an average of 30 swab samples per hour.
Viatris (VTRS) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Viatris (VTRS) beats on Q2 earnings and sales. The company raises annual guidance.
Bayer's (BAYRY) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2021.
Amicus (FOLD) Q2 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Amicus (FOLD) reports narrower-than-expected Q2 loss. The sales figure also beat estimates. Following encouraging results and positive progress with pipeline candidates, the stock rises.
Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock up.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Vertex Pharma and Twilio highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Vertex Pharma and Twilio highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Vertex Pharmaceuticals (VRTX)
by Kevin Cook
Scientific innovation in the treatment of cystic fibrosis bolsters success and pipeline confidence
Horizon's (HZNP) Q2 Earnings and Revenues Beat, Stock Up
by Zacks Equity Research
Horizon (HZNP) beats on both earnings and revenues in Q2. Sales soared on account of the relaunch of the thyroid eye disease drug Tepezza. As a result, stock rises.
Clovis (CLVS) Q2 Earnings Miss, PARP Drug Rubraca Sales Down
by Zacks Equity Research
Clovis (CLVS) reports wider-than-expected loss for second-quarter 2021. Sales of the company's sole marketed drug, Rubraca, decreased year over year due to COVID-19 impacts.
Moderna (MRNA) Q2 Earnings Top, COVID-19 Vaccine Brings $4.2B
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine continues to enjoy robust demand. The company delivered 199 million doses of its COVID-19 vaccine during the second quarter.
Here is Why Growth Investors Should Buy Vertex (VRTX) Now
by Zacks Equity Research
Vertex (VRTX) possesses solid growth attributes, which could help it handily outperform the market.
Deciphera (DCPH) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Deciphera (DCPH) posts wider-than-expected loss in the second quarter due to rising R&D costs. Sales beat estimates on the encouraging uptake of Qinlock.
Zacks.com featured highlights include: Walmart, Vertex Pharma, Medical Properties Trust, TriNet Group and TriMas Corp
by Zacks Equity Research
Zacks.com featured highlights include: Walmart, Vertex Pharma, Medical Properties Trust, TriNet Group and TriMas Corp
Ultragenyx (RARE) Q2 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx Pharmaceutical's (RARE) Q2 sales increase year over year while loss widens.
Rising P/E: A Trick to Land on 5 Winning Stocks
by Sanghamitra Saha
Want to try a different approach? Tap five stocks with increasing P/E ratios.
Vertex (VRTX) Q2 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Vertex's (VRTX) earnings and sales beat estimates in the second quarter of 2021. The company raises revenue guidance for the year.